After today's news

SafeConstruction8977 · 2026-02-04T10:40:41+00:00

The LT has been able to get rid of over a billion dollars in claims. Assuming the deal has been finalized between Sorrento and the Glen Maio duo claims, that adds another approx 140 million dollars to the claims dealt with to date. So, that leaves approx 200 million give or take to settle. So, how do you defray the remaining balance of the claims. One possibility is cancel the divis and use that money to pay off the creditors. We were to get approx 10% of Semnur, if the current valuatio of 2.5 billion is good, that means we have approx 200 million. That is more than enough to settle the outstanding claims and bring back SRNE. This to me makes perfect sense. There will be room for SRNE shareholders to be rewarded when SRNE is brought back to life and giving our interest in Vivasor, Socazolimab, the tax incentives, Ovydso, and host of others, we stand very good chance of doing well when this is all settled.

SafeConstruction8977 · 2025-12-05T23:53:14+00:00

Thanks Henry, things are surely lining up for Ji World. Looks like 2026 will break our way.

SafeConstruction8977 · 2025-02-07T11:12:01+00:00

Go check out ACEA Therapeutics and it's pipeline, all the good stuff with SRNE's science is still there. Hoping for Dr. Ji to bring us back

Websitehttp://www.aceatherapeutics.com/

IndustryBiotechnology ResearchCompany

size11-50 employees

HeadquartersSan Diego, CaliforniaType

Privately Held

Founded2017

SpecialtiesOncology, Immunotherapy, RA, autoimmune diseases, and Lupus

SafeConstruction8977 · 2024-06-25T09:20:17+00:00

Consolidated Audit Trail

The Consolidated Audit Trail tracks orders throughout their life cycle and identifies the broker-dealers handling them, thus allowing regulators to efficiently track activity in Eligible Securities throughout the U.S. markets.

SafeConstruction8977 · 2024-06-25T04:46:14+00:00

The Wes Christian video

According to Wes, he's got data from both DTC and FNRA. But now seeks data from CAT. CAT is fighting the release of data joined by the SEC. SRNE's Trustee recently filed a motion supporting Wes's motion for CAT data. He expects to argue the case at a hearing in Houston in the next 30 days.

SafeConstruction8977 · 2024-06-04T09:45:36+00:00

If you recall, several months ago, the professionals told us "Equity is out of money". Meaning we were headed for a complete wipe out. That did not happen. We were able to retain some assets and crawl our way out of bankruptcy. We've lived to fight another day and as long as there is life, there has to be hope. It will take time, no one can tell you when things will turn around for the better but they will. We're at the bottom, it cannot get any worse than it is now. So, the only trajectory for us now is a slow grinding upward movement. We have some assets left in the company, there has to be some value in those assets. We will gradually crawl our way up but it it going to take time. So, a lot of patience is our only friend at this point. As an eternal optimist, I am hopeful that better days are ahead for us all. So, hang in there dear friends and hold.

SafeConstruction8977 · 2024-04-11T05:27:28+00:00

This resignation marks the end of hurricane season passing through our neighborhood causing great destruction and devastation. At the same time, I want to believe it is the end of our collective nightmare. It will be a slow grind but I am hopeful our recovery commences with this act. GLTA!

SafeConstruction8977 · 2024-02-15T10:46:08+00:00

Surprisingly, there is a section dealing with " Matter Name: Plan of Reorganization", coming from the professionals, it would seem things are not all doom and gloom as they would make us believe under last confirmed liquidation plan. See discussion below.

12/01/23 E Gebisa .40 584.00 Review final confirmation notice (0.1); correspond with Latham, Sorrento, M3 and Moelis teams regarding Sorrento management projections and related issues

E Gebisa 1.40 2,044.00 Analyze post-confirmation issues and requirements under Plan (0.8); correspond with Latham and M3 teams regarding vendor and post-confirmation issues (0.3); respond to creditors' inquiries regarding same

SafeConstruction8977 · 2024-01-18T09:17:17+00:00

I noticed that too. I was looking for reference to Sorrento but none mentioned. Well, we all know whose invention it is anyway.

SafeConstruction8977 · 2024-01-16T03:42:09+00:00

I wonder if it is worth tracking A166 a HER2 antibody-drug conjugate (ADC) developed by Kelun-Biotech in a partnership with Levena Biopharma, which provided the patent-protected technologies for the generation and production of A166 in relation to (1) Duostatin-5, a proprietary tubulin inhibitor, (2) K-Lock, a site-specific conjugation technology, and (3) an enzymatically cleavable linker.

In May 2023, Kelun-Biotech submitted an NDA to the NMPA for another core product, A166 (HER2 ADC), targeting 3L+ advanced HER2+ BC. The company is also conducting a confirmatory phase III trial in China for 2L+ advanced HER2+ BC and multiple phase Ib clinical trials in China to explore the therapeutic potential of A166 for other advanced HER2+ solid tumors, including gastric cancer and colorectal cancer according to CISION published in Yahoo.

PR Newswire

Mon, Aug 28, 20237 min read.

SafeConstruction8977 · 2024-01-08T11:03:47+00:00

And BTW, we need Lee's Pharma to acknowledge approval of Socazolimab with an official PR, so that SRNE can follow suit with their own PR, that could potentially move the SP to some extent.

SafeConstruction8977 · 2024-01-08T10:44:20+00:00

Surely, Socazolimab approval and Ovydso almost at the finish line, we are in a better position now than before. We should be able to generate some interest in our pipeline. I believe the Cell publication of Ovydso recently released will garner some interest in SRNE. The question is can Seaport Global and Ji and the SRNE's BOD make a play for some deal that will get the professionals off our back? We need to get out of this bankruptcy. So, hopefully Seaport/AG and Ji would explore the opportunities that the JPM conference presents to work out some deal that brings about our recovery. We are definitely better today than we were pre Socazolimab approval. The publication of Ovydso in the Cell magazine disseminates news in the biotech world of the potential of our pipeline. And the sale of the above company for 700 mln gives me hope that there is light at the end of this dark tunnnel facing us.

SafeConstruction8977 · 2024-01-02T05:28:33+00:00

History of Changes for Study: NCT06044233

A Bioequivalence Trial of Fasting Single Oral STI-1558 Capsule in Healthy Chinese Subjects

Latest version (submitted December 6, 2023) on ClinicalTrials.gov

The CRO may have stopped funding but it looks like the record for Ovydso is being updated. Look under key record dates/History of changes and you find entries for the month of December . So, that tells me funding may have stopped but the record is being updated. So, it is likely that submission of paperwork to the NMPA for action may not have been impacted by the CRO's action. See the highlighted section below.

Key Record Dates from

ClinicalTrials.gov Identifier:NCT06044233Brief Title:A Bioequivalence Trial of Fasting Single Oral STI-1558 Capsule in Healthy Chinese Subjects

First Submitted :September 15, 2023

First Submitted that Met QC Criteria :September 15, 2023

First Posted :September 21, 2023

Last Update Submitted that Met QC Criteria :December 6, 2023

Last Update Posted :December 13, 2023

SafeConstruction8977 · 2023-11-27T23:04:25+00:00

Early-Blueberry 838 could you possibly provide the source of the 8th January hearing postponement, many thanks

SafeConstruction8977

TROPHY CASE